Ticker > Company >

Akums Drugs & Pharma share price

Akums Drugs & Pharmaceuticals Ltd.

NSE: AKUMS BSE: 544222 SECTOR: Pharmaceuticals & Drugs  21k   22   12

495.55
-0.90 (-0.18%)
BSE: 21 Feb 04:01 PM

Price Summary

Today's High

₹ 515.9

Today's Low

₹ 495

52 Week High

₹ 1174.85

52 Week Low

₹ 483

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

7799.66 Cr.

Enterprise Value

7952.64 Cr.

No. of Shares

15.74 Cr.

P/E

0

P/B

3.43

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  144.66

CASH

73.31 Cr.

DEBT

226.29 Cr.

Promoter Holding

75.26 %

EPS (TTM)

₹  -10.51

Sales Growth

12.22%

ROE

-72.66 %

ROCE

-20.46%

Profit Growth

-231.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.22%
3 Year19.92%
5 Year16.15%

Profit Growth

1 Year-231.91%
3 Year-4.82%
5 Year-217.19%

ROE%

1 Year-72.66%
3 Year-41.22%
5 Year-27.97%

ROCE %

1 Year-20.46%
3 Year-17.18%
5 Year-14.16%

Debt/Equity

1.5728

Price to Cash Flow

31.46

Interest Cover Ratio

-4.6208

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 75.26 0.00
Sep 2024 75.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 19.9176188378848% for the Past 3 years.
  • The company has an efficient Cash Conversion Cycle of 35.6359 days.
  • The company has a high promoter holding of 75.26%.
  • Promoter stake has increased from 0% to 75.26% in the last 1 quarter.

 Limitations

  • The company has shown a poor profit growth of -4.81782885841887% for the Past 3 years.
  • Company has a poor ROE of -41.2170333333333% over the past 3 years.
  • Company has a poor ROCE of -17.1789333333333% over the past 3 years
  • Company has low Interest coverage ratio of -4.6208.
  • Tax rate is low at -60.7366.
  • The company has a low EBITDA margin of -3.18782% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024
Net Sales 317.28 328.35 337.41
Total Expenditure 273.59 285.28 303.38
Operating Profit 43.68 43.07 34.03
Other Income 26.18 32.12 33.84
Interest 6.21 4.18 2.29
Depreciation 9.38 9.39 10.68
Exceptional Items 0 0 0
Profit Before Tax 54.27 61.62 54.89
Tax 12.4 11.25 13.72
Profit After Tax 41.88 50.37 41.17
Adjusted EPS (Rs) 2.93 3.29 2.69

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 736.91 837.44 1162.06 1286.83 1444.12
Total Expenditure 696.98 810.73 1524.1 1088.92 1570.78
Operating Profit 39.92 26.7 -362.04 197.91 -126.66
Other Income 65.52 54.51 58.48 140.12 94.12
Interest 4.34 0.82 3.65 13.18 18.31
Depreciation 25.26 26.1 27.76 30 32.69
Exceptional Items 0 -249.5 0 -144.53 -19.39
Profit Before Tax 75.85 -195.2 -334.98 150.32 -102.93
Tax 24.99 -49.77 46.8 24.89 62.52
Net Profit 50.86 -145.43 -381.78 125.43 -165.45
Adjusted EPS (Rs.) 3.55 -10.16 -26.69 8.77 -11.56

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 1.3 1.3 14.31 28.61 28.61
Total Reserves 711.02 565.75 171.23 282.89 115.27
Borrowings 0 0 0 21.88 15.63
Other N/C liabilities 535.99 551.55 1092.56 1061.14 1434.19
Current liabilities 177.95 146 535.86 496.56 501.74
Total Liabilities 1426.26 1264.6 1813.95 1891.07 2095.43
Assets
Net Block 225.84 229.09 233.5 253.15 298.48
Capital WIP 1.13 1.26 0.52 16.13 8.57
Intangible WIP 0 0 0 0.12 0.09
Investments 81.18 130.45 141.39 139.16 138.92
Loans & Advances 587.56 508.57 858.15 937.52 1094.95
Other N/C Assets 36.41 24.63 25.24 23.92 21.28
Current Assets 494.14 370.6 555.16 521.08 533.14
Total Assets 1426.26 1264.6 1813.95 1891.07 2095.43
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 75.85 -195.2 -334.98 150.32 -102.93
Adjustment -26.46 -19.27 -11.93 55.51 344.01
Changes in Assets & Liabilities -22.68 -28.45 99.58 -81.51 43.12
Tax Paid -46.32 -4.9 -7.19 -30.3 -36.29
Operating Cash Flow -21.75 55.57 228.31 94.01 247.91
Investing Cash Flow -241.71 -99.96 -297.96 -202.17 -165.44
Financing Cash Flow 301.53 2.6 94.99 89.9 -20.74
Net Cash Flow 38.07 -41.79 25.34 -18.26 61.72

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024%
promoters 75.26 75.26
akums master trust (sanje... - 40.79
lata jain 0.01 0.01
sandeep jain 17.24 17.24
sanjeev jain 17.23 17.23
akums master trust 40.79 -
PARTICULARS Sep 2024% Dec 2024%
investors 24.74 24.74
akums employee benefits t... 2.73 2.73
franklin india smaller co... 1.71 2.12
llp 0.01 0.02
ruby qc investment holdin... 4.62 4.62
smallcap world fund, inc 2.15 2.15

Annual Reports

No Annual reports exist for this company.Report us

Ratings & Research Reports

Company Presentations

Company News

Akums Drugs secures patent for 'Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation' 15 Feb, 5:00 PM Akums Drugs and Pharmaceuticals informs about newspaper publication 15 Feb, 4:06 PM Akums Drugs and Pharmaceuticals reports 66% drop in Q3 consolidated net profit 7 Feb, 4:27 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs & Pharma - Quaterly Results 6 Feb, 5:58 PM Akums Drugs and Pharmaceuticals informs about analyst meet 3 Feb, 2:58 PM Akums Drugs and Pharmaceuticals informs about disclosure 22 Jan, 12:31 PM Akums Drugs enters into agreement for manufacture, supply of selected pharmaceutical formulations 24 Dec, 3:28 PM Akums Drugs and Pharmaceuticals informs about updates 26 Nov, 5:11 PM Akums Drugs’ arm collaborates with Jagdale Industries 26 Nov, 3:42 PM Akums Drugs enters into exclusive Master Sales Agreement with Caregen 19 Nov, 2:51 PM Akums Drugs and Pharmaceuticals informs about press release 11 Nov, 2:38 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs & Pharmaceuticals - Quaterly Results 9 Nov, 5:51 PM Akums Drugs and Pharmaceuticals enters into MoU with Government of Republic of Zambia 18 Oct, 2:27 PM Akums Drugs & Pharmaceuticals enters into license & distribution agreement with Triple Hair Inc 16 Oct, 3:45 PM Akums Drugs launches new product Famotidine, Calcium Carbonate and Magnesium Hydroxide 10 Oct, 9:22 AM Akums Drugs and Pharmaceuticals informs about closure of trading window 30 Sep, 12:33 PM Akums Drugs gets patent certificate from Government of India 13 Sep, 10:46 AM Akums Drugs and Pharmaceuticals informs about newspaper publication 26 Aug, 12:41 PM Akums Drugs & Pharmaceuticals - Quaterly Results 24 Aug, 5:30 PM Akums Drugs and Pharmaceuticals informs about earnings call 23 Aug, 2:49 PM Akums Drugs’ arm starts second production facility at Haridwar manufacturing unit 23 Aug, 11:00 AM Akums Drugs and Pharmaceuticals coming with IPO to raise upto Rs 1893.21 crore 27 Jul, 12:58 PM Akums Drugs and Pharmaceuticals gets SEBI’s nod for IPO 9 Jul, 2:40 PM Akums Drugs and Pharmaceuticals files DRHP with SEBI 14 Feb, 12:38 PM

Akums Drugs & Pharma Stock Price Analysis and Quick Research Report. Is Akums Drugs & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Akums Drugs & Pharma and its performance over the period of time. Akums Drugs & Pharma stock price today is Rs 496.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Akums Drugs & Pharma cash from the operating activity was Rs 247.907 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Akums Drugs & Pharma has a Debt to Equity ratio of 1.5728 , which is a weak indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Akums Drugs & Pharma , the EPS growth was -231.9072 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Akums Drugs & Pharma has OPM of -8.77060685442127 % which is a bad sign for profitability.
     
  • ROE: Akums Drugs & Pharma have a poor ROE of -72.6647 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Akums Drugs & Pharma is Rs 496.7. One can use valuation calculators of ticker to know if Akums Drugs & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Akums Drugs & Pharma
X